Abstract: A method for archiving monitoring data by enabling real-time analysis within a live database. A processor receives a set of parameters, which is selected based on monitoring data of a system application. The processor determines a historical schema of monitoring data and a retention period for a current schema of monitoring data, based on the set of parameters. The processor performs an impact analysis of the historical schema and retention period of the monitoring data. Upon acceptance of the impact analysis, the processor generates the historical schema which is applied to a table of monitoring data, populated by copying monitoring data from the current schema to the historical schema, within the live database. The processor removes monitoring data exceeding the rolling retention period from both the current schema and historical schema, based on the rolling retention period of the current schema.

Abstract: A method for archiving monitoring data by enabling real-time analysis within a live database. A processor receives a set of parameters, which is selected based on monitoring data of a system application. The processor determines a historical schema of monitoring data and a retention period for a current schema of monitoring data, based on the set of parameters. The processor performs an impact analysis of the historical schema and retention period of the monitoring data. Upon acceptance of the impact analysis, the processor generates the historical schema which is applied to a table of monitoring data, populated by copying monitoring data from the current schema to the historical schema, within the live database. The processor removes monitoring data exceeding the rolling retention period from both the current schema and historical schema, based on the rolling retention period of the current schema.

Abstract: A method for archiving monitoring data by enabling real-time analysis within a live database. A processor receives a set of parameters, which is selected based on monitoring data of a system application. The processor determines a historical schema of monitoring data and a retention period for a current schema of monitoring data, based on the set of parameters. The processor performs an impact analysis of the historical schema and retention period of the monitoring data. Upon acceptance of the impact analysis, the processor generates the historical schema which is applied to a table of monitoring data, populated by copying monitoring data from the current schema to the historical schema, within the live database. The processor removes monitoring data exceeding the rolling retention period from both the current schema and historical schema, based on the rolling retention period of the current schema.

Abstract: A method for archiving monitoring data by enabling real-time analysis within a live database. A processor receives a set of parameters, which is selected based on monitoring data of a system application. The processor determines a historical schema of monitoring data and a retention period for a current schema of monitoring data, based on the set of parameters. The processor performs an impact analysis of the historical schema and retention period of the monitoring data. Upon acceptance of the impact analysis, the processor generates the historical schema which is applied to a table of monitoring data, populated by copying monitoring data from the current schema to the historical schema, within the live database. The processor removes monitoring data exceeding the rolling retention period from both the current schema and historical schema, based on the rolling retention period of the current schema.

Abstract: Reducing resource requirements in an instrumented process tracing system, a process having a top instrumented process and a nested hierarchy of instrumented sub-processes. A computer receives a plurality of instrumented process data from the top process and the sub-processes, each datum including a process identifier, a process type, a top process identifier, and a process completion elapsed time. Based on the computer determining that the process identifier and the top process identifier in the datum received are equivalent: if the process completion elapsed time in the datum received is determined to be less than a threshold value, the computer writes a summary of the plurality of instrumented process data to a data store, and if the process completion elapsed time in the datum received is determined to not be less than the threshold value, the computer writes the plurality of instrumented process data to the data store.

Abstract: Reducing resource requirements in an instrumented process tracing system, a process having a top instrumented process and a nested hierarchy of instrumented sub-processes. A computer receives a plurality of instrumented process data from the top process and the sub-processes, each datum including a process identifier, a process type, a top process identifier, and a process completion elapsed time. Based on the computer determining that the process identifier and the top process identifier in the datum received are equivalent: if the process completion elapsed time in the datum received is determined to be less than a threshold value, the computer writes a summary of the plurality of instrumented process data to a data store, and if the process completion elapsed time in the datum received is determined to not be less than the threshold value, the computer writes the plurality of instrumented process data to the data store.

Abstract: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R?1; R is selected from the group comprising Formula (A?), (B), (C), (D), or (E), with R1 and/or R?1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.

Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R2?, L, Het, p and p? are as defined herein, compositions containing them, and their use as medicinal products.

Abstract: The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R?1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A?), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs.

Abstract: This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.

Abstract: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R?1; R is selected from the group comprising Formula (A?), (B), (C), (D), or (E), with R1 and/or R?1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.

Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R2?, L, Het, p and p? are as defined herein, compositions containing them, and their use as medicinal products.

Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

Abstract: This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.

Abstract: This invention relates to 3-aryl-1,2-benzisoxazole derivatives of formula (I) to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.

Abstract: 1-Aryl-3-(indol-5-yl)prop-2-en-1-ones, compositions containing them and use thereof are disclosed and claimed. The present invention relates specifically to novel substituted 1-aryl-3-(indol-5-yl)prop-2-en-1-ones of formula (I) having a therapeutic activity, particularly, in oncology.